X0306 4 2016-02-03 true 0001432732 TriVascular Technologies, Inc. TRIV 0001304124 Thomas Robert C/O TRIVASCULAR TECHNOLOGIES, INC. 3910 BRICKWAY BLVD. SANTA ROSA CA 95403 true false false false Common Stock 2016-02-03 4 M false 16523.00 2.43 A 106639.00 D Common Stock 2016-02-03 4 F false 7145.00 5.62 D 99494.00 D Common Stock 2016-02-03 4 D false 9378.00 D 90116.00 D Common Stock 2016-02-03 4 D false 90116.00 D 0.00 D Stock Options (Right to buy) 2.43 2016-02-03 4 M false 16523.00 0.00 D 2022-08-29 Common Stock 16523.00 0.00 D These shares were withheld by the issuer as payment of the exercise price and calculated for the purposes of the deemed exercise of the options, contingent upon closing of the Merger (as defined below), utilizing the closing price of the issuers common stock on January 28, 2016. These shares were disposed of pursuant to the merger agreement between the issuer and Endologix, Inc. (such transaction, the Merger). In connection with the closing of the Merger, the reporting person received 0.6312 share of Endologix common stock and $0.34 in cash for each share of issuer common stock held by such reporting person, for a total consideration of $4.95 per share based upon the closing price of Endologix common stock on February 2, 2016. These stock options became 100% vested in connection with the Merger. /s/ Michael Kramer, Attorney-In-Fact Robert W. Thomas 2016-02-04